Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triac Trial II: Tiratricol in Children With MCT8 Deficiency
2019-003370-35Phase 2Completed
- Sponsor
- Egetis Therapeutics
- Start
- Dec 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acapatamab in Allan-Herndon-Dudley syndrome (AHDS), sponsored by Egetis Therapeutics. Primary endpoint: Primary: Change in GMFM-88 score versus natural history. Started Dec 2019; status: completed.
02
Drugs
acapatamab
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on 2019-003370-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003370-35.